Antibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-51391 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Cyclin B3 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Immunogen sequence: KMCASQRKQS CQEESLAVQD VNMEEDSFFM ESMSFKKKPK TEESIPTHKL SSLKKKCTIY GKICHFRKPP VLQTTICGAM SSIKKPTTEK ETLFQELSVL QEKHTTEHEM S Highest antigen sequence identity to the following orthologs: Mouse - 29%, Rat - 32%.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.3 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of Cyclin B3 in human cell line A-431 shows positivity in nucleus but excluded from the nucleoli. Samples were probed using a Cyclin B3 Polyclonal Antibody (Product # PA5-51391).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of Cyclin B3 in human testis using a Cyclin B3 Polyclonal Antibody (Product # PA5-51391) shows strong nuclear positivity in a subset of cells in seminiferous ducts.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of Cyclin B3 in human liver using a Cyclin B3 Polyclonal Antibody (Product # PA5-51391) shows no positivity in hepatocytes as expected.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical staining of Cyclin B3 in human testis and liver tissues using Cyclin B3 Polyclonal Antibody (Product # PA5-51391). Corresponding CCNB3 RNA-seq data are presented for the same tissues.